Nav: Home

Role of rogue protein PAK4 confirmed in pancreatic cancer cells

February 17, 2017

A new study that confirms the role of a protein called PAK4 in the movement and growth of pancreatic cancer cells could help researchers find new ways to tackle the disease.

The work, funded by national charity Pancreatic Cancer Research Fund, uncovers new evidence that PAK4 plays a key role in enabling cancer cells to grow and to spread from the pancreas into other areas of the body, a process called metastasis.

The researchers, from Kings College London, also found evidence of a close relationship between PAK4 and a well-researched cancer pathway called the phosphoinositide 3-kinase pathway (PI3K). PI3K is responsible for regulating the growth and survival of cancer cells and several inhibitors targeting it have already been developed.

"We've seen hints before that PAK4 and PI3K pathway are linked, but finding evidence of their interaction is an important advance because it gives us additional avenues to explore in testing promising new inhibitor compounds that can tackle this disease," says Dr Claire Wells, who led the study. "Such studies could lead the way to thinking about combination therapy that could target both PAK4 and PI3K"

PAK4 is found at particularly high levels in pancreatic cancer cells and this work forms part of a wider investigation into the precise role of this protein in cancer progression. Dr Wells' team has previously published research on the importance of PAK4 in other types of cancer, including prostate, breast and melanoma.

The work complements existing studies into PAK4, but advances existing knowledge by using a sophisticated model system that better mimics a pancreatic tumour, alongside films of the cells as they grow and develop.

The team also studied what happened when PAK4 was removed from the cells, using an RNA silencing technology that can prevent production of specific proteins.

"This technique allows us to look in detail at the structure and development of the cells, and we can clearly see that, if you remove PAK4 from those cells, they lose their ability to be really invasive," explains Dr Wells.

"One of the big problems with pancreatic cancer is recurrence - even for people who can have surgery, there's a really high level of recurrence," adds Dr Wells. "If we can develop therapeutics that would suppress the movement of cells out of the pancreas, they could be given to patients following surgery and help to prevent that recurrence and spread of the disease."

Ultimately this research confirms PAK4 as a promising target for new drug compounds, a number of which have already been identified by the researchers for testing. The team is also planning further research to find out more about why pancreatic cancer cells rely on PAK4 and what other proteins and pathways PAK4 is interacting with to drive cell growth and migration.
-end-
Notes to editors:

The paper, "PAK4 interacts with p85 alpha: implications for pancreatic cancer cell migration", by Helen King, Kiruthikah Thillai, Andrew Whale, Prabhu Arumugam, Hesham Eldaly, Hemant M Kocher and Claire M Wells, is published in Scientific Reports: http://www.nature.com/articles/srep42575

About pancreatic cancer
  • Pancreatic cancer is the 5th most common cause of cancer-related death in the UK.
  • Over 9,000 people are diagnosed each year in UK.
  • The five-year survival rate is 3% - the worst survival rate of any common cancer.
  • The average survival time from diagnosis to death is 6 months.
  • Symptoms are often mistaken for less lethal conditions and there is no early diagnostic test.
  • Most patients are diagnosed when the disease has already spread to other organs.
  • Only around 10-15% of patients are eligible for surgery, currently the only potentially curative treatment.
  • Less than 2% of national cancer research funding is spent on pancreatic cancer.


About Pancreatic Cancer Research Fund (PCRF)

PCRF is the only national charity exclusively funding research into pancreatic cancer. To date, the charity has funded 45 research projects worth over £7 million. In January 2016 PCRF launched a £2 million national pancreas tissue bank - the first in the world - to accelerate research into the disease. All funding used to support research comes from public fundraising and donations.

About King's College London

King's College London is one of the top 25 universities in the world (2016/17 QS World University Rankings) and among the oldest in England. King's has more than 27,600 students (of whom nearly 10,500 are graduate students) from some 150 countries worldwide, and some 6,800 staff.

King's has an outstanding reputation for world-class teaching and cutting-edge research. In the 2014 Research Excellence Framework (REF) King's was ranked 6th nationally in the 'power' ranking, which takes into account both the quality and quantity of research activity, and 7th for quality according to Times Higher Education rankings. Eighty-four per cent of research at King's was deemed 'world-leading' or 'internationally excellent' (3* and 4*). The university is in the top seven UK universities for research earnings and has an overall annual income of more than £684 million.

Pancreatic Cancer Research Fund

Related Cancer Articles:

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.
More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.
New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.
American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.
Oncotarget: Cancer pioneer employs physics to approach cancer in last research article
In the cover article of Tuesday's issue of Oncotarget, James Frost, MD, PhD, Kenneth Pienta, MD, and the late Donald Coffey, Ph.D., use a theory of physical and biophysical symmetry to derive a new conceptualization of cancer.
Health indicators for newborns of breast cancer survivors may vary by cancer type
In a study published in the International Journal of Cancer, researchers from the UNC Lineberger Comprehensive Cancer Center analyzed health indicators for children born to young breast cancer survivors in North Carolina.
Few women with history of breast cancer and ovarian cancer take a recommended genetic test
More than 80 percent of women living with a history of breast or ovarian cancer at high-risk of having a gene mutation have never taken the test that can detect it.
Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
More Cancer News and Cancer Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Rethinking Anger
Anger is universal and complex: it can be quiet, festering, justified, vengeful, and destructive. This hour, TED speakers explore the many sides of anger, why we need it, and who's allowed to feel it. Guests include psychologists Ryan Martin and Russell Kolts, writer Soraya Chemaly, former talk radio host Lisa Fritsch, and business professor Dan Moshavi.
Now Playing: Science for the People

#538 Nobels and Astrophysics
This week we start with this year's physics Nobel Prize awarded to Jim Peebles, Michel Mayor, and Didier Queloz and finish with a discussion of the Nobel Prizes as a way to award and highlight important science. Are they still relevant? When science breakthroughs are built on the backs of hundreds -- and sometimes thousands -- of people's hard work, how do you pick just three to highlight? Join host Rachelle Saunders and astrophysicist, author, and science communicator Ethan Siegel for their chat about astrophysics and Nobel Prizes.